(Q38543596)

English

Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

scientific article published on 10 June 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 September 2017

1 reference

Europe PubMed Central

Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. (English)

1 reference

Europe PubMed Central

4 September 2017

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

M-L Chang

1

1 reference

Europe PubMed Central

4 September 2017

Y-F Liaw

2

1 reference

Europe PubMed Central

4 September 2017

S J Hadziyannis

3

1 reference

Europe PubMed Central

4 September 2017

language of work or name

0 references

publication date

10 June 2015

1 reference

Europe PubMed Central

4 September 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

4 September 2017

42

1 reference

Europe PubMed Central

4 September 2017

3

1 reference

Europe PubMed Central

4 September 2017

243-257

1 reference

Europe PubMed Central

4 September 2017

Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Residual amount of HBV DNA in serum is related to relapse in chronic hepatitis B patients after cessation of nucleos(t)ide analogs

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Control of cccDNA function in hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Clinical events after cessation of lamivudine therapy in patients recovered from hepatitis B flare with hepatic decompensation

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13272

21 January 2018

Identifiers

10.1111/APT.13272

1 reference

Europe PubMed Central

4 September 2017

1 reference

Europe PubMed Central

4 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38543596&oldid=1590419240"